Published in Eur J Pharm Biopharm on April 02, 2012
Peptide fibrils with altered stability, activity, and cell selectivity. Biomacromolecules (2013) 0.84
A novel approach to decrease sialic acid expression in cells by a C-3-modified N-acetylmannosamine. J Biol Chem (2014) 0.78
Physiological Effects of Ac4ManNAz and Optimization of Metabolic Labeling for Cell Tracking. Theranostics (2017) 0.75
Extreme Activity of Drug Nanocrystals Coated with A Layer of Non-Covalent Polymers from Self-Assembled Boric Acid. Sci Rep (2016) 0.75
Cell surface engineering by a modified Staudinger reaction. Science (2000) 8.09
Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 4.85
The sialic acids. XI. A periodate-resorcinol method for the quantitative estimation of free sialic acids and their glycosides. J Biol Chem (1971) 4.42
Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science (1997) 3.34
Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res (2005) 2.08
Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology. Nat Chem Biol (2006) 1.98
Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J (2001) 1.94
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
Multiple drug resistance mechanisms in cancer. Mol Biotechnol (2010) 1.84
Sialyltransferases in cancer. Glycoconj J (2003) 1.83
Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-D-hexosamines as precursors. J Biol Chem (1992) 1.59
Metabolic glycoengineering: sialic acid and beyond. Glycobiology (2009) 1.45
DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol (2007) 1.44
Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J Biol Chem (2001) 1.22
Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem (2007) 1.22
Expression cloning of the Golgi CMP-sialic acid transporter. Proc Natl Acad Sci U S A (1996) 1.20
Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuraminic acid precursor. J Biol Chem (1998) 1.16
Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acyl-modified N-acetylmannosamine analogs in Jurkat cells. J Biol Chem (2004) 1.09
Regioisomeric SCFA attachment to hexosamines separates metabolic flux from cytotoxicity and MUC1 suppression. ACS Chem Biol (2008) 1.06
Carbohydrate engineered cells for regenerative medicine. Adv Drug Deliv Rev (2010) 1.04
Sialic acid metabolism in sialuria fibroblasts. J Biol Chem (1991) 1.02
Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett (2005) 1.01
Sialic acid metabolism is involved in the regulation of gene expression during neuronal differentiation of PC12 cells. Glycoconj J (2008) 0.98
Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem (2009) 0.97
Effects of D-glucosamine, D-mannosamine, and 2-deoxy-D-glucose on the ultrastructure of ascites tumor cells in vitro. Cancer Res (1972) 0.97
Cancer: Chemotherapy counteracted. Nature (2010) 0.97
Fluorination of mammalian cell surfaces via the sialic acid biosynthetic pathway. Bioorg Med Chem Lett (2008) 0.92
Synthesis of non-natural ManNAc analogs for the expression of thiols on cell-surface sialic acids. Nat Protoc (2006) 0.91
Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci (2001) 0.88
Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs (2010) 0.86
Multifactorial nature of tumor drug resistance. Exp Oncol (2010) 0.86
Metabolic labeling of glycoconjugates with photocrosslinking sugars. Methods Enzymol (2010) 0.85
The pH sensitivity of histidine-containing lytic peptides. J Pept Sci (2009) 0.84
New amino sugar analogues are incorporated at different rates into glycoproteins of mouse organs. Experientia (1993) 0.83
Sialylation using N-glycolylneuraminyl phosphite donors to synthesize Neu5Gc-containing glycans. Carbohydr Res (2009) 0.79
Susceptibility of Staphylococcus aureus biofilms to reactive discharge gases. Biofouling (2011) 0.97
The activity of a small lytic peptide PTP-7 on Staphylococcus aureus biofilms. J Microbiol (2011) 0.94
Lytic peptides with improved stability and selectivity designed for cancer treatment. J Pharm Sci (2012) 0.92
Constructing bioactive peptides with pH-dependent activities. Peptides (2009) 0.89
PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release (2008) 0.87
Peptide self-assembly on cell membranes to induce cell lysis. Biomacromolecules (2012) 0.84
The pH sensitivity of histidine-containing lytic peptides. J Pept Sci (2009) 0.84
Peptide fibrils with altered stability, activity, and cell selectivity. Biomacromolecules (2013) 0.84
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A (2009) 0.83
Insights into discharge argon-mediated biofilm inactivation. Biofouling (2013) 0.80
Specific interactions between diphenhydramine and alpha-helical poly(glutamic acid)--a new ion-pairing complex for taste masking and pH-controlled diphenhydramine release. Eur J Pharm Biopharm (2008) 0.79
Improved stability and selectivity of lytic peptides through self-assembly. Biochem Biophys Res Commun (2007) 0.79
Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria. Arch Microbiol (2012) 0.78
Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. J Control Release (2005) 0.78
Low power gas discharge plasma mediated inactivation and removal of biofilms formed on biomaterials. Curr Appl Phys (2013) 0.78
The potential roles of cell surface pHs in bioactive peptide activation. Chem Biol Drug Des (2014) 0.75
The inactivation of Staphylococcus aureus biofilms using low-power argon plasma in a layer-by-layer approach. Biofouling (2015) 0.75
Enhanced anticancer activity of drug nanoparticles formulated with β-cyclodextrin. Anticancer Drugs (2016) 0.75
Preparation and anticancer activity evaluation of an amorphous drug nanocomposite by simple heat treatment. Anticancer Drugs (2017) 0.75